China will refine its drug pricing system with 14 measures, Xinhua reports
- The plan includes optimising launch pricing for innovative and newly listed drugs
- Will use payment standards to guide pricing, encouraging reasonable pharmacy retail prices, strengthening supply and price stability for shortage medicines, and enhancing monitoring, enforcement, audit oversight and drug value assessment to keep prices within a reasonable range.
Context
China's initiative to refine its drug pricing system with a set of 14 measures signals a regulatory shift aimed at optimizing drug affordability and supply stability. This is significant for pharmaceutical companies as it aligns pricing strategies with government standards, potentially impacting margins and the market for both domestic and international firms operating in China.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#EU SESSION#ASIAN EQUITIES